Annovis Bio closes $21M public offering of 5.25M units with warrants at $4.00/unit

Annovis Bio, Inc.

Offering of 5,250,000 units (1 share + 1 warrant) at $4.00 per unit; gross proceeds $21M.
Warrants exercisable at $5.00 per share, immediately exercisable, 5-year term.
Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.
Offering closed on February 4, 2025; underwritten by ThinkEquity LLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.